Alnylam Invests $5M in Canadian RNAi Company
Luke Timmerman6/2/08
Alnylam Pharmaceuticals, the Cambridge, MA-based biotech developing drugs using RNA interference technology, said today it made a $5 million investment in Vancouver-based Tekmira Pharmaceuticals in order to gain access to its delivery technologies. The deals gives Alnylam expanded rights to intellectual property held by Protiva Biotherapeutics before it merged with Tekmira, and to new intellectual property created by the combined company, Alnylam said in a statement.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
